trending Market Intelligence /marketintelligence/en/news-insights/trending/na5pWYmC4Q7Z4cC6bEZ-XA2 content esgSubNav
In This List

Abbvie to continue manufacturing component for lymphoma drug

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Abbvie to continue manufacturing component for lymphoma drug

Seattle Genetics Inc. asked AbbVie Inc. to continue manufacturing a component for its Adcetris drug.

The companies extended a development and supply agreement under which AbbVie will manufacture the anti-CD30 monoclonal antibody through Dec. 31, 2025, as opposed to Aug. 22, 2021, previously. The contract will automatically renew unless terminated by either party.

Adcetris is used for the treatment of classical Hodgkin lymphoma, a form of cancer that affects the immune system.